Triazine‐based heterocycles have emerged as privileged scaffolds in anticancer drug discovery owing to their structural versatility, favorable physicochemical properties, and broad biological activity. Among them, 1,2,3‐, 1,2,4‐, and 1,3,5‐triazine derivatives and their hybrid architectures have demonstrated significant cytotoxic and antiproliferative effects against diverse cancer types through multiple mechanisms, including kinase inhibition, DNA damage, tubulin disruption, and apoptosis induction. Recent advances in synthetic methodologies and structure–activity relationship (SAR) studies have enabled precise modulation of their pharmacological profiles, leading to improved efficacy, reduced toxicity, and the ability to overcome multidrug resistance. This review comprehensively summarizes the synthesis, biological evaluation, and mechanistic insights of triazine‐based anticancer hybrids, highlighting emerging design strategies and therapeutic trends. The collective findings underscore the potential of triazine scaffolds as promising candidates for the development of next‐generation anticancer therapeutics.
Goel et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: